文献速递创伤骨科骨质疏松与代谢性骨病

神经毁损阻滞与非手术髋部骨折患者死亡率的关系:荷兰全国人群研究

Use of neurolytic nerve blocks and mortality in nonoperative management of hip fracture patients : a nationwide population study in the Netherlands.
PubMed 文献 · Bone Joint J · 2026-08-01

该回顾性人群队列研究纳入2024年全年荷兰70岁及以上非手术管理的髋部骨折患者1415例(平均年龄86岁),其中45%接受了神经毁损阻滞。接受阻滞者更衰弱、依赖程度更高、营养不良和无法活动比例更高且更多为移位骨折。阻滞组7天死亡率显著更低(24.9% vs 39.0%,p<0.001),但3个月(74.9% vs 68%,p=0.036)和6个月(89.7% vs 72.9%,p=0.027)死亡率更高;30天调整风险比为0.73(95%CI 0.61–0.88;p=0.001)。

要点

  • 非手术髋部骨折患者中45%接受神经毁损阻滞,该组患者基线更衰弱。
  • 阻滞组7天死亡率显著低于未阻滞组(24.9% vs 39.0%,p<0.001)。
  • 阻滞组3个月和6个月死亡率反而更高,30天调整HR为0.73。

核心结论

  • 神经毁损阻滞已成为荷兰非手术髋部骨折管理的一部分,与更低的短期死亡率相关。
  • 本非手术队列较既往荷兰队列衰弱程度更低,提示患者选择范围有所扩大。

研究设计与样本

  • 回顾性人群队列研究,纳入2024年1月1日至2024年12月31日期间荷兰70岁及以上非手术治疗的髋部骨折患者。
  • 共纳入1415例非手术管理患者,平均年龄86岁(SD 6.75),其中633例(45%)接受神经毁损阻滞。

主要发现

  • 接受神经毁损阻滞的患者更衰弱、依赖程度更高、营养不良和无法活动比例更高,且更多被诊断为移位骨折。
  • 阻滞组7天死亡率显著更低:24.9%(n=120)vs 39.0%(n=138),p<0.001。
  • 阻滞组3个月死亡率更高:74.9%(n=361)vs 68%(n=68.1),p=0.036。
  • 阻滞组6个月死亡率更高:89.7%(n=384)vs 72.9%(n=258),p=0.027。
  • 30天调整风险比为0.73(95%CI 0.61–0.88;p=0.001)。

临床怎么用

  • 对于极衰弱、非手术管理的髋部骨折患者,可考虑使用酚类神经毁损阻滞作为长期镇痛手段。
  • 需权衡阻滞带来的短期生存获益与中长期死亡率升高的关联,个体化决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Nonoperative management may be suitable for very frail hip fracture patients; in these instances, neurolytic nerve blocks with phenol could act as a long-term analgesic, with potentially fewer disadvantages compared with systemic analgesia. While neurolytic nerve blocks are being used more frequently in end-of-life care, there are limited data on how often they are used, and what long-term outcomes they achieve in patients with hip fractures. This study aims to evaluate the association between neurolytic nerve block use and mortality in patients with hip fractures managed nonoperatively, while also exploring the characteristics of patients who receive these blocks. METHODS: A retrospective population-based cohort study was conducted including patients with a hip fracture aged 70 years and older, who were treated nonoperatively between 1 January 2024 and 31 December 2024. The primary outcome was mortality, comparing patients who received a neurolytic block with those who did not. RESULTS: Of 1,415 nonoperatively managed patients (mean age 86 years (SD 6.75)), 633 (45%) received neurolytic nerve blocks. These patients were more frail, had greater levels of dependence, malnourishment, and immobility, and were diagnosed with a displaced fracture more often than those who did not receive a block. Nerve block patients also showed significantly lower mortality at seven days (24.9% (n = 120) vs 39.0% (n = 138); p < 0.001), but higher mortality at three months (74.9% (n = 361) vs 68% (n = 68.1); p = 0.036) and six months (89.7% (n = 384) vs 72.9% (n = 258); p = 0.027). The adjusted hazard ratio at 30 days was 0.73 (95% CI 0.61 to 0.88; p = 0.001). CONCLUSION: Neurolytic nerve blocks have emerged as part of nonoperative hip fracture management in the Netherlands and are associated with lower short-term mortality. Furthermore, our nonoperatively managed cohort appeared less frail than earlier Dutch cohorts, suggesting a broadening of patient selection.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. van Bremen HE, Lommerse MI, Hegeman JH, et al. Use of neurolytic nerve blocks and mortality in nonoperative management of hip fracture patients : a nationwide population study in the Netherlands. Bone Joint J. 2026. PMID: 42537998. doi:10.1302/0301-620X.108B8.BJJ-2025-1465.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。